{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:53:48Z","timestamp":1777553628453,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dose-Response"],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy of 3\/4-drugs\u2019 group with 1-drug\u2019s or 2-drugs\u2019 groups in coronavirus disease 2019 (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3\/4, 1 or 2 drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The viral clearance rates of the 3\/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug\u2019s or 2-drugs\u2019 groups (P &lt; 0.05). The median viral clearance days in 3\/4-drugs group (13.5 days) were longer than 1-drug\u2019s or 2-drugs\u2019 groups (both were 9 days) (P &lt; 0.001). The patients\u2019 discharge rates in the 3\/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug\u2019s or 2 drugs\u2019 group (P &lt; 0.05). The median length of hospitalization in the 3\/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3\/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients\u2019discharge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1559325820949740","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T11:05:52Z","timestamp":1597403152000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China"],"prefix":"10.1177","volume":"18","author":[{"given":"Xingsheng","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, People\u2019s Republic of China"},{"name":"*Xingsheng Hu and Chunhong Hu\u00a0contributed equally."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, People\u2019s Republic of China"},{"name":"*Xingsheng Hu and Chunhong Hu\u00a0contributed equally."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nanchong Central Hospital, Nanchong, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Chengdu Medical College, Chengdu, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Intensive care unit, Changsha Central Hospital of Nanhua University, Changsha, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Central Hospital of Xiangtan, Xiangtan, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4233-8822","authenticated-orcid":false,"given":"Xiangyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"bibr1-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"bibr2-1559325820949740","unstructured":"World Health Organization. Published 2020. Accessed July 8, 2020. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200708-covid-19-sitrep-170.pdf?sfvrsn=bca86036_2."},{"issue":"6","key":"bibr3-1559325820949740","first-page":"399","volume":"9","author":"Chan KS","year":"2003","journal-title":"Hong Kong Me d J"},{"key":"bibr4-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.012658"},{"key":"bibr5-1559325820949740","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587188-96"},{"key":"bibr6-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.24.3222"},{"key":"bibr7-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70920-X"},{"key":"bibr8-1559325820949740","unstructured":"Chinese Government. Diagnosis and treatment protocol for novel coronavirus pneumonia (7th interim edited). China NHCOTPSRO. Published 2020. Accessed June 29, 2020. http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-03\/04\/con-tent_5486705.htm."},{"key":"bibr9-1559325820949740","unstructured":"World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. Published 2019. Accessed May 15, 2020. https:\/\/www.who.int\/publications\/m\/item\/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols."},{"key":"bibr10-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-14-8"},{"issue":"2","key":"bibr11-1559325820949740","first-page":"215","volume":"49","author":"Chen J","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"bibr12-1559325820949740","unstructured":"Tang W, Cao ZJ, Han MF, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. Med Rxiv [Preprint]. Published 2020. Accessed May 15, 2020. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.10.20060558v2."},{"key":"bibr13-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"issue":"1","key":"bibr14-1559325820949740","first-page":"66","volume":"22","author":"Mou XH","year":"2004","journal-title":"Chin J infect Dis"},{"key":"bibr15-1559325820949740","doi-asserted-by":"crossref","unstructured":"Li YP, Xie ZW, Lin WY, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI). Med Rxiv [Preprint]. Published 2020. Accessed May 15, 2020. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.19.20038984v2.","DOI":"10.1016\/j.medj.2020.04.001"},{"key":"bibr16-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz544"},{"key":"bibr17-1559325820949740","doi-asserted-by":"crossref","unstructured":"Zhuang MW, Cheng Y, Zhang J, et al. Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV (Or SARS-CoV-2). Infection J Med Virol [Preprint]. Published 2020. doi:10.1002\/jmv.26139. Accessed June 29, 2020. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jmv.26139.","DOI":"10.1002\/jmv.26139"},{"key":"bibr18-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"bibr19-1559325820949740","unstructured":"Back of obtaining of urgent right to use of remdesivir: how to view different outcomes between China and America? Published 2020. Accessed May 15, 2020. https:\/\/baijiahao.baidu.com\/s?id=1665574582573807627&wfr=spider&for=pc."},{"key":"bibr20-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"bibr21-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1172OC"},{"key":"bibr22-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030343"},{"key":"bibr23-1559325820949740","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2395-8"},{"key":"bibr24-1559325820949740","unstructured":"Saha A, Sharma AR, Bhattacharya M, Sharma G, Sang-Soo L, Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res [preprint]. 2020:S0188\u20134409(20)30699\u20138. Accessed June 8, 2020. https:\/\/www.Sciencedirect.com\/science\/article\/pii\/S0188440920306998?via%3Dihub."}],"container-title":["Dose-Response"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1559325820949740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1559325820949740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1559325820949740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:02:27Z","timestamp":1777399347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1559325820949740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,1]]}},"alternative-id":["10.1177\/1559325820949740"],"URL":"https:\/\/doi.org\/10.1177\/1559325820949740","relation":{},"ISSN":["1559-3258","1559-3258"],"issn-type":[{"value":"1559-3258","type":"print"},{"value":"1559-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"article-number":"1559325820949740"}}